Advertisement
New Zealand markets close in 2 hours 32 minutes

  • NZX 50

    11,736.77
    +60.78 (+0.52%)
     

  • NZD/USD

    0.6147
    +0.0051 (+0.83%)
     

  • NZD/EUR

    0.5654
    +0.0042 (+0.74%)
     

  • ALL ORDS

    8,148.20
    +28.00 (+0.34%)
     

  • ASX 200

    7,876.60
    +24.90 (+0.32%)
     

  • OIL

    79.06
    -0.20 (-0.25%)
     

  • GOLD

    2,428.60
    +2.70 (+0.11%)
     

  • NASDAQ

    18,713.80
    +39.61 (+0.21%)
     

  • FTSE

    8,416.45
    -7.75 (-0.09%)
     

  • Dow Jones

    39,872.99
    +66.22 (+0.17%)
     

  • DAX

    18,726.76
    -42.20 (-0.22%)
     

  • Hang Seng

    19,346.16
    +125.54 (+0.65%)
     

  • NIKKEI 225

    38,748.96
    -197.97 (-0.51%)
     

  • NZD/JPY

    96.0100
    +0.8430 (+0.89%)
     

Sandoz reaches agreement with Amgen over patent dispute

Reuters
·1-min read

ZURICH, April 30 (Reuters) - Swiss generic and biosimilar manufacturer Sandoz said on Tuesday it had reached an agreement with U.S. drugmaker Amgen resolving all patent litigation related to its U.S. denosumab biosimilars.

The agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances, Sandoz said in a statement.

"The terms of the agreement will not impact our previously disclosed 2024 guidance," Sandoz said.

Patent infringement proceedings were initially filed by Amgen in the U.S. Federal District Court for the District of New Jersey in May 2023, the statement said. (Writing by Dave Graham Editing by Miranda Murray)